Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial
Objectives. This study aimed to examine the efficacy and safety of acupoint catgut embedding (ACE) for obesity over a 16-week treatment period using sham stimulation as the control. Methods. A multicenter, randomised, parallel, sham-controlled trial was conducted from February 10, 2017, to May 15, 2018. Men with waistlines ≥85 cm and women with ≥80 cm at three sites were randomised to receive eight sessions (over 16 weeks) of ACE (n = 108) or sham ACE (n = 108) with skin penetration at sham acupoints. The catgut was embedded once every two weeks using two alternating sets of acupoints. The follow-up lasted for an additional 24 weeks. The primary outcome was the percentage waistline reduction from baseline to week 16. Results. We included 216 individuals in the intention-to-treat analysis. At 16 weeks, the rate of waistline reduction was 8.80% (95% confidence interval (CI), 7.93% to 9.66%) in the ACE group and 4.09% (95% CI, 3.18% to 5.00%) in the sham control group, with a between-group difference of 4.71% (95% CI, 3.47% to 5.95%; P < 0.0001). This difference persisted throughout the entire follow-up period (between-group difference after 24-week additional weeks, 4.94% (95% CI, 3.58% to 6.30%); P < 0.001). The subgroup analyses of waistline by sex (male/female) revealed treatment effects of 1.93 (95% CI, −0.37 to 4.23, P = 0.1) in the male group and 3.19 (95% CI, 1.99 to 4.39, P < 0.001) in the female group. The adverse event analysis suggested that ACE and laboratory tests confirmed the safety of ACE. Discussion. ACE for 16 weeks could decrease the waistline and weight and was safe for the treatment of obesity. Further research is needed to evaluate the long-term efficacy and sex differences. This trial is registered with NCT02936973..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Evidence-Based Complementary and Alternative Medicine - (2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia Chen [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2022/4780019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01836313X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01836313X | ||
| 003 | DE-627 | ||
| 005 | 20230501180205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2022/4780019 |2 doi | |
| 035 | |a (DE-627)DOAJ01836313X | ||
| 035 | |a (DE-599)DOAJ39d9d2b3e2414ae492eb07e2ee00dc16 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RZ201-999 | |
| 100 | 0 | |a Xia Chen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives. This study aimed to examine the efficacy and safety of acupoint catgut embedding (ACE) for obesity over a 16-week treatment period using sham stimulation as the control. Methods. A multicenter, randomised, parallel, sham-controlled trial was conducted from February 10, 2017, to May 15, 2018. Men with waistlines ≥85 cm and women with ≥80 cm at three sites were randomised to receive eight sessions (over 16 weeks) of ACE (n = 108) or sham ACE (n = 108) with skin penetration at sham acupoints. The catgut was embedded once every two weeks using two alternating sets of acupoints. The follow-up lasted for an additional 24 weeks. The primary outcome was the percentage waistline reduction from baseline to week 16. Results. We included 216 individuals in the intention-to-treat analysis. At 16 weeks, the rate of waistline reduction was 8.80% (95% confidence interval (CI), 7.93% to 9.66%) in the ACE group and 4.09% (95% CI, 3.18% to 5.00%) in the sham control group, with a between-group difference of 4.71% (95% CI, 3.47% to 5.95%; P < 0.0001). This difference persisted throughout the entire follow-up period (between-group difference after 24-week additional weeks, 4.94% (95% CI, 3.58% to 6.30%); P < 0.001). The subgroup analyses of waistline by sex (male/female) revealed treatment effects of 1.93 (95% CI, −0.37 to 4.23, P = 0.1) in the male group and 3.19 (95% CI, 1.99 to 4.39, P < 0.001) in the female group. The adverse event analysis suggested that ACE and laboratory tests confirmed the safety of ACE. Discussion. ACE for 16 weeks could decrease the waistline and weight and was safe for the treatment of obesity. Further research is needed to evaluate the long-term efficacy and sex differences. This trial is registered with NCT02936973. | ||
| 653 | 0 | |a Other systems of medicine | |
| 700 | 0 | |a Wei Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Dan Wei |e verfasserin |4 aut | |
| 700 | 0 | |a Ji-Ping Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a Wei Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a De-Guang Ding |e verfasserin |4 aut | |
| 700 | 0 | |a Yang Jiao |e verfasserin |4 aut | |
| 700 | 0 | |a Hong-Ling Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Jia-Jia Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Feng Zhong |e verfasserin |4 aut | |
| 700 | 0 | |a Feng Gao |e verfasserin |4 aut | |
| 700 | 0 | |a Yi-Ting Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Yi-Wei Zheng |e verfasserin |4 aut | |
| 700 | 0 | |a Yan-Ji Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Qiao Huang |e verfasserin |4 aut | |
| 700 | 0 | |a Xian-Tao Zeng |e verfasserin |4 aut | |
| 700 | 0 | |a Zhong-Yu Zhou |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Evidence-Based Complementary and Alternative Medicine |d Hindawi Limited, 2004 |g (2022) |w (DE-627)DOAJ000122912 |x 1741427X |7 nnns |
| 773 | 1 | 8 | |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2022/4780019 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/39d9d2b3e2414ae492eb07e2ee00dc16 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2022/4780019 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1741-4288 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 | ||